- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
AI-Enabled X-Rays Help Detect Lung Cancer Risk in 50,000 Patients Worldwide: Study Shows - Video
|
Overview
AstraZeneca, in partnership with health-tech company Qure.ai, has successfully completed over 5 million artificial intelligence (AI)-enabled chest X-rays (CXRs) across more than 20 countries in Asia, the Middle East, Africa, and Latin America. The initiative, part of the World Economic Forum's EDISON Alliance 1 Billion Lives Challenge, underscores the potential of AI in enhancing early lung cancer detection, particularly in resource-limited healthcare settings.
The screening program uses Qure.ai’s proprietary qXR® AI technology to analyze routine CXRs for signs of lung abnormalities, including nodules that may be indicative of cancer. Initiated in 2020 under AstraZeneca’s A.Catalyst Network, the collaboration aims to support early identification of high-risk individuals and improve access to diagnostic follow-ups like low-dose CT scans. Out of the 5 million scans conducted, nearly 50,000 individuals were identified with lung nodules at high risk for cancer and were referred for further diagnostic testing.
The program has seen successful implementations in countries such as Colombia, El Salvador, and India. AstraZeneca is now working closely with Ministries of Health and policymakers to scale this approach and integrate AI-enabled screening into national lung health strategies. By directing limited resources toward high-risk cases identified through AI, the initiative enhances the efficiency and reach of cancer detection efforts, especially in low- and middle-income countries where access to advanced imaging and specialists is often constrained.
This achievement highlights how AI-driven healthcare solutions can bridge gaps in early detection and improve outcomes for diseases like lung cancer, reinforcing AstraZeneca's global commitment to equitable cancer care and innovative health technology adoption.
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes," said Ti Hwei How, Vice President, International Oncology, AstraZeneca. "Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Reference: https://www.qure.ai/news_press_coverages/A-new-era-for-lung-cancer-detection-AI-enabled-risk-assessment-reaches-5-million-people-around-the-world
Speakers
Dr. Garima Soni
BDS, MDS(orthodontics)
Dr. Garima Soni holds a BDS (Bachelor of Dental Surgery) from Government Dental College, Raipur, Chhattisgarh, and an MDS (Master of Dental Surgery) specializing in Orthodontics and Dentofacial Orthopedics from Maitri College of Dentistry and Research Centre. At medical dialogues she focuses on dental news and dental and medical fact checks against medical/dental mis/disinformation